Morgan Stanley initiated coverage of Procept BioRobotics (PRCT) with an Overweight rating and $105 price target Procept offers a clinically differentiated treatment for patients with enlarged prostates who often suffer from lower urinary tract symptoms and the firm’s work suggests plenty of penetration remaining for PRCT in prostates with only 8% penetration today, leaving “a long tail for growth,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Procept BioRobotics initiated with a Hold at Jefferies
- PROCEPT BioRobotics (PRCT) Continues to Invest in Labor-Saving Robotics
- Procept BioRobotics price target raised to $105 from $95 at Truist
- Procept BioRobotics 1.92M share Spot Secondary priced at $91.00
- Procept BioRobotics announces $175M common stock offering
Questions or Comments about the article? Write to editor@tipranks.com